Activity Overview
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
is a rare, immune-mediated disorder of the peripheral nerves and nerve roots.
Advances in our understanding of CIDP pathophysiology, including the role of
pathogenic IgG autoantibodies, have expanded the therapeutic landscape with
targeted treatments such as neonatal Fc receptor (FcRn) antagonists and
complement inhibitors. While these offer new opportunities, they also introduce
complexity in treatment selection, sequencing, and transitions. This
CME-certified activity features three expert faculty engaging in a mix of
didactic and case-based discussions, focusing on the latest diagnostic and
treatment strategies in CIDP.
Target Audience
This educational activity is directed toward neurologists,
neuroimmunologists, neuromuscular specialists, specialty NPs and PAs, and other
HCPs involved in the management of CIDP.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the disease burden associated with CIDP.
- Integrate evidence-based strategies to differentiate CIDP from other relevant differential diagnoses.
- Apply patient-specific factors to individualize CIDP management
Karissa Gable, MD
Duke University
Professor of Neurology
Disclosures: Advisor, consultant, Fee for Service Recipient: Sanofi,
Immunovant, Grifols, CSL, Behring, Argenx, Takenda, Dianthus Grant/Research Funding: PI of TAK-881 Study Takeda.
Jeffrey Allen, MD
University of Minnesota
Professor of Neurology
Disclosures: Advisor, consultant, Fee for Service Recipient: 2nd
MD, Alexion, Alnylam, Akcea, Therapeutics, Annexon, Argenx SE, CSL Behring,
Dianthus, Grifols, Hansa, Immunovant, Immunopharm, ImmunoAbs, Johnson &
Johnson, Pfizer, Sanofi, Takeda, UCB Speakers Bureau: Alexion, CSL Behring, Johnson
& Johnson, Takeda, UCB
Suraj Muley, MD, FAAN
Arizona State University
Director of Neurology
Professor of Medicine
Disclosures: Advisor, Consultant, Fee for Service Recipient: Alexion, Argenx Speakers Bureau: Alexion, CSL Behring, Takeda, Catalyst.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information
presented and apply their own clinical judgment when considering patient care
decisions.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here